LIXTE Biotechnology Acquires Liora Technologies Europe Ltd
November 25, 2025
LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) has completed the acquisition of Liora Technologies Europe Ltd., a UK-based developer of the LiGHT proton therapy system. The deal brings Liora's proprietary LiGHT System and Daresbury-based operations into LIXTE as a wholly owned subsidiary to expand the company's capabilities into radiotherapy and pursue joint treatment-center revenue models.
- Buyers
- LIXTE Biotechnology Holdings, Inc.
- Targets
- Liora Technologies Europe Ltd.
- Industry
- Medical Devices
- Location
- Cheshire, United Kingdom
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
LIXTE Biotechnology Holdings to Acquire NOMAD Transportable Power Systems
June 12, 2026
Energy
LIXTE Biotechnology Holdings, Inc. (NASDAQ: LIXT) has entered into a definitive agreement to acquire 100% of NOMAD Transportable Power Systems, Inc. (NOMAD). Upon closing (expected around July 1, 2026), LIXTE plans to be renamed NOMAD Power Solutions and reposition as a deployable, utility-grade battery energy storage company.
-
Pharmaron Acquires 82.54% of Biortus Biosciences
October 28, 2025
Healthcare Services
Pharmaron Beijing Co., Limited has entered into a definitive Share Purchase Agreement to acquire 82.54% of Biortus Biosciences Co., Ltd. and its affiliates. The transaction is expected to close after satisfaction of customary closing conditions and is intended to strengthen Pharmaron’s structure-based drug discovery and protein science capabilities.
-
Telix Pharmaceuticals to Acquire RLS (USA) to Expand North American Radiopharmacy Manufacturing and Distribution
September 22, 2024
Healthcare Services
Telix Pharmaceuticals Limited has agreed to acquire RLS (USA) Inc. from its parent company, RLS Group Ltd., to expand Telix’s North American radiopharmaceutical manufacturing and distribution platform. The deal leverages RLS’s 31 Joint Commission-accredited radiopharmacies to build a radiometal production and distribution network and improve capacity for PET, SPECT, and therapeutic isotopes.
-
Full-Life Technologies Acquires Focus‑X Therapeutics
November 28, 2022
Biotechnology
Full‑Life Technologies, a global radiotherapeutics company, agreed to acquire New Jersey‑based Focus‑X Therapeutics to expand its peptide‑focused radiopharmaceutical pipeline. Focus‑X shareholders are eligible for an upfront payment plus up to $245 million in development, regulatory and sales milestones and royalties; the deal was expected to close in Q1 2023.
-
Burlington Medical (Peninsula Capital Partners portfolio) Acquires Lite Tech (XenoLite)
June 28, 2022
Medical Devices
Burlington Medical, a portfolio company of Peninsula Capital Partners, has acquired Lite Tech, Inc. (d/b/a XenoLite), a Norristown, Pennsylvania manufacturer of lightweight, lead-free radiation-protective aprons and related products. The deal is an add-on to the Burlington platform and expands its manufacturing capabilities and product offering in the healthcare radiation-protection market, creating what Burlington describes as the world's largest manufacturer of radiation-protective aprons.
-
Warburg Pincus and Tilia Acquire FlexXray from Levine Leichtman Capital Partners
July 26, 2021
Food & Beverage
Warburg Pincus and Tilia Holdings have acquired FlexXray, a leading provider of x-ray inspection and recovery services for the food industry, from Levine Leichtman Capital Partners. The investment is intended to support FlexXray's growth and expansion of its food-safety inspection capabilities and geographic reach; financial terms were not disclosed.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.